Tuesday, April 2, 2013

Revance Therapeutics Raises $33M

Mountain View-based Revance Therapeutics, a developer of specialty biopharmaceuticals, said today that it has raised $33M in a Series E financing. The funding came from its existing investors, including Essex Woodlands, NovaQuest Pharma Opportunities Fund, Delphi Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Bio*One Capital and Pac-Link Ventures, Palo Alto Fund, along with others. The firm said the investment also included "significant investment" from new investors. The firm said it will use the financing for a Phase 3 trial for its product for reducing the severity of crow's feet wrinkles. The firm also said it has converted $71M in convertible debt into the new, Series E funding. More information »